Translate page

iCMLf

Alliance

    NICE - National Institute for Health and Care Excellence

    NICE Guidance: Asciminib for treating myeloid leukemia after 2 or more tyrosine kinase inhibitors
    Published August 2022

    Click here to view the full guidance

    Click 'Read more'  to find more NICE guidances

    NICE Guidance: Ponatinib for treating chronic myeloid leukemia and acute lymphoblastic leukemia
    Published June 2017
    Click here to view the full guidance

    NICE Guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib
    Published December 2016
    Click here to veiw the full guidance

    NICE Guidance: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukemia
    Published December 2016
    Click here to see the full guidance

    NICE Guidance: Bosutinib for previously treated chronic myeloid leukemia
    Published August 2016
    Click here to see the full guidance

    NICE Guidance on the use of imatinib for chronic myeloid leukaemia
    Published October 2003; last modified January 2016
    Click here to view the full guidance